{
  "document_id": "HOUSE_OVERSIGHT_028421",
  "filename": "IMAGES-009-HOUSE_OVERSIGHT_028421.txt",
  "text": "ps://www.youtube.com/watch?v=Rlfs6hthwGo\", \"range\": {\"length\":18,\"start\":172}, \"type\": \"lin\n\nk\"}],\"identifier\":\" anf-body-\n\n49\",\"“inlineTextStyles\":[{\"range\": {\"length\":234,\"start\":0},\"textsStyle\":\" anf-ts-\n\ni\"}, {\"range™: {\"length\":234,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\",\"text\":\"Since Labor Day, Mr. Menendezad€™s campaign, perhaps ina\n\nsign of vulnerability, has aggressively ramped up its advertising campaign, with a\nmajority of the political attacks accusing Mr. Hugin of raising drug prices to maximize\nprofits.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n50\", \"inlineTextStyles\": [{\"range\": {\"length\":332,\"start\":0},\"textsStyle\":\" anf-ts-\n\ni\"}, {\"range™: {\"length\":332,\"start\":0},\"textStyle\":\"_anf-ts-1\"}],\"layout\":\"default—\nbody\", \"role\":\"body\", \"text\":\"In 2017, after Mr. Hugin had stepped down as chief\nexecutive and becom xecutive chairman, the company suffered two major setbacks in its\ndevelopment pipeline: A drug it had hoped would be a breakthrough in treating Crohnda€™s\ndisease failed to outperform a control group and Otezla, a psoriasis drug, badly missed\nsales expectations.\",\"type\"™:\"text\"}, {\"additions\"™: [{\"URL\":\"https://ir.celgene.com/press-—\nreleases/press-release-details/2017/Celgene-Provides-Update-on-GED-0301-mongersen\nInflammatory-Bowel-Diseas\nProgram/default.aspx\", \"range\": {\"length\":39, \"start\":21}, \"type\"™:\"link\"}, {\"URL\":\"https://i\nr.celgene.com/press-releases/press-release-details/2017/Celgene-Provides-Update-on-GED\n0301-mongersen-Inflammatory-Bowel-Diseas\nProgram/default.aspx\", \"range\": {\"length\":20,\"start\":60}, \"type\"™:\"link\"}, {\"URL\":\"https://w\nww.streetinsider.com/Analystt+Comments/Celgene+%28CELG%$29%3A+Pricet+tIncreases+Add+8ctiInti\nT+-\n+Suntrust/13411298 html\", \"range\": {\"length\":64, \"start \":161}, \"type\"™:\"link\"}], \"identifier\"\n\nW\n\n7\" anf-body-\n51\", \"inlineTextStyles\": [{\"range\": {\"length\":364,\"start\":0},\"textsStyle\":\" anf-ts-\ni\"}, {\"range™: {\"length\":364,\"start\":0},\"textStyle\":\"_anf-ts-1\"}],\"layout\":\"default-\n\nbody\", \"role\":\"body\", \"text\":\"On the same day that Celgene announced it was scrapping the\nCrohnaé€™s disease drug, it increased the price of Revlimid from $17,014 a bottle to\n$18,546, according to a report by Yatin Suneja, an analyst who follows the industry. It\nwas the third price increase of Revlimid in 2017, representing a nearly 20 percent\nprice increase for the drug from the previous\nyear.\", \"type™:\"text\"}, {\"additions\"™: [{\"URL\":\"https://d18rn0p25nwréd.cloudfront.net/CIK-\n0000816284/ddd3eeae-cal0e-48c5-8132\n\n54186f548874. pdf\", \"range\": {\"length\":20,\"start\":0},\"type\"™:\"link\"}],\"identifier\":\" anf-\nbody-52\", \"inlineTextStyles\": [{\"range\"™:{\"length\":156,\"start\":0},\"textStyle\":\" anf-ts-\ni\"},{\"range\"™:{\"length\":156,\"start\":0},\"textStyle\":\"_anf-ts-1\"}],\"layout\":\"default-\n\nbody\", \"role\": \"body\", \"text\"™:\"In financial filings, Celgene said these price hikes were a\nmain reason the drugaé&€™s net sales increased in 2017 by about $1.2 billion over the\n\nprevious year.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n53\",\"inlineTextStyles\":[{\"range\": {\"length\":314,\"start\":0},\"textstyle\":\" anf-ts-\n\nI\"}, {\"range™: {\"length\":314,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-—\nbody\", \"role\":\"body\", \"text\":\"Ronny Gal, a securities analyst at Sanford C. Bernstein &\n\nCompany who follows the pharmaceutical industry, said drug companies have generally\nbeen dA€cetone deafa€ when it comes to raising the price of their monopoly products.\na€eCelgene clearly has been there, but has not been any worse than the main players, a4€\n\nhe said.\", \"type\": \"text\"}, {\"identifier\":\" anf-body-\n54\",\"inlineTextStyles\": [{\"range\": {\"length\":412,\"start\":0},\"textsStyle\":\" anf-ts-\ni\"}, {\"range\"™: {\"length\":412,\"start\":0},\"textStyle\":\"_anf-ts-1\"}],\"layout\":\"default—\nbody\", \"role\":\"body\", \"text\":\"The tactics can carry a human cost. Last year, Elaine\n\nKodish, a 76-year-old retir from Los Angeles, briefly stopped taking Revlimid after\nher Medicare drug plan required she pay more than $450 a month for the drug that keeps\nher multiple myeloma in check. Ms. Kodish said she bought stock in Celgene when sh\nstarted taking Revlimid in 2016, as a way of supporting a company she believed was\n\nkeeping her alive.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n55\",\"inlineTextStyles\": [{\"range\": {\"length\":364, \"start\":0},\"textsStyle\":\" anf-ts-\n\ni\"}, {\"range™: {\"length\":364,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"But after a series of price increases hav xposed her to\n\nballooning out-of-pocket costs 4€\" she has since returned to taking Revlimid, which now\ncosts her about $785 per month 4€\" she said she recently sold her stake. A€el4e™m\ngrateful to the drug companies, dond€™t get me wrong,a€ Ms. Kodish said. d€ceHowever,\nthey canaéd€™t be compensated on the backs of people who are\ndying.a€\",\"type\":\"text\"}, {\"components\": [{\"identifier\":\" anf-heading6-\ni\",\"layout\":\"related-coverage-heading\", \"role\": \"heading6\", \"text\": \"RELATED\nCOVERAGE\", \"textStyle\":\"related-\n\ncoverage\", \"type\": \"text\"}, {\"additions\"™: [{\"URL\":\"https://www.nytimes.com/2017/07/25/healt\nh/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer\n\nHOUSE_OVERSIGHT_028421",
  "metadata": {
    "original_filename": "IMAGES-009-HOUSE_OVERSIGHT_028421.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 5191,
    "word_count": 505,
    "line_count": 89,
    "import_date": "2025-11-19T21:47:47.341455",
    "prefix": "IMAGES-009"
  }
}